Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
Free COVID tests return as this variant now accounts for nearly 60% of cases
As free tests are now available, one COVID-19 variant continues to be the most prevalent in the United States.
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot ...
This first-to-market launch showcases Teva’s proven strengths in complex generic formulations and enhances Teva’s strategic ...
Too Old to Operate12 小时
FDA Approves Miplyffa for Treatment of Niemann-Pick Disease, Type C
The U.S. Food and Drug Administration has approved Miplyffa (arimoclomol), an oral medication for the treatment of ...